^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Ituxredi (rituximab biosimilar)

i
Other names: DRL_RI
Associations
Company:
Abbott, CinnaGen, Dr. Reddy’s, EMD Serono, Fresenius Kabi, R-Pharm
Drug class:
CD20 inhibitor
Related drugs:
Associations
10ms
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
1year
RI-01-007: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products (clinicaltrials.gov)
P3, N=140, Completed, Dr. Reddy's Laboratories Limited | Active, not recruiting --> Completed
Trial completion
|
Ituxredi (rituximab biosimilar)
1year
Real-world outcomes of diffuse large B-cell lymphoma in the biosimilar era. (PubMed, Front Oncol)
Reditux™ and Ristova were comparable in real-world setting. ISRCTN registry, identifier (ISRCTN13301166).
Journal • Real-world evidence • Real-world
|
BCL2 (B-cell CLL/lymphoma 2)
|
Ituxredi (rituximab biosimilar)
2years
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=39, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2024 --> Jul 2022
Trial completion • Trial completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Ituxredi (rituximab biosimilar)
over2years
FLINTER: Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma (clinicaltrials.gov)
P3, N=317, Active, not recruiting, Dr. Reddy's Laboratories Limited | Recruiting --> Active, not recruiting | Trial completion date: Sep 2020 --> Mar 2023 | Trial primary completion date: Sep 2020 --> Sep 2022
Enrollment closed • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
3years
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=39, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Mar 2021 --> Jul 2021
Clinical • Trial completion date • Trial primary completion date
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)
almost4years
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
P2, N=39, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting
Clinical • Enrollment closed
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
CD20 positive
|
Rituxan (rituximab) • Ituxredi (rituximab biosimilar)